MedTrace Logo

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

NCT00050271 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV patients who have taken certain anti-HIV drugs.

Conditions

  • HIV Infections
  • Peripheral Nervous System Diseases

Interventions

DRUG

Acetyl-L-carnitine

Sponsors & Collaborators

  • Neurologic AIDS Research Consortium (NARC)

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Victor Valcour, M.D. · University of Hawaii

  • Russell Bartt, M.D. · Cook County Hospital and Rush-Presbyterian St. Luke's Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2007-01-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050271 on ClinicalTrials.gov